Progyny, Inc. (NASDAQ:PGNY) Receives Consensus Rating of "Moderate Buy" from Analysts

Key Points

• Consensus "Moderate Buy": Thirteen analysts rate PGNY a "Moderate Buy" (nine buys, four holds) with an average 12‑month price target of $27.91.
• Quarterly beat and guidance: Progyny reported Q results above expectations (EPS $0.48 vs. $0.38 est.; revenue $318.4M vs. $314.3M) and set FY2026 guidance of $1.83–$1.95 EPS with Q1 2026 guidance of $0.42–$0.45.
• Ownership and trading note: An EVP sold 4,657 shares last quarter (insiders sold 7,455 total) while insiders retain 9.90% ownership and institutional investors own 94.93%; shares trade around $17.67 with a $1.38B market cap, well below analyst targets.

Progyny, Inc. (NASDAQ:PGNY - Get Free Report) has been given an average recommendation of "Moderate Buy" by the thirteen analysts that are presently covering the stock, MarketBeat Ratings reports. Four research analysts have rated the stock with a hold recommendation and nine have assigned a buy recommendation to the company. The average 12 month target price among analysts that have updated their coverage on the stock in the last year is $27.9091.

PGNY has been the topic of a number of research analyst reports. Citigroup upgraded Progyny to an "outperform" rating in a report on Tuesday, January 20th. Barclays lowered their price target on Progyny from $29.00 to $23.00 and set an "overweight" rating on the stock in a report on Friday, March 20th. Truist Financial lowered their price target on Progyny from $34.00 to $28.00 and set a "buy" rating on the stock in a report on Monday, March 2nd. Citizens Jmp upgraded Progyny from a "market perform" rating to an "outperform" rating and set a $30.00 price target on the stock in a report on Tuesday, January 20th. Finally, Jefferies Financial Group reiterated a "buy" rating and set a $30.00 price target on shares of Progyny in a report on Friday, March 6th.

Insider Buying and Selling at Progyny

In other news, EVP Allison Swartz sold 4,657 shares of Progyny stock in a transaction on Tuesday, March 3rd. The stock was sold at an average price of $17.40, for a total transaction of $81,031.80. Following the transaction, the executive vice president owned 89,879 shares in the company, valued at approximately $1,563,894.60. The trade was a 4.93% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Insiders sold a total of 7,455 shares of company stock worth $129,515 in the last quarter. Insiders own 9.90% of the company's stock.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of PGNY. Royal Bank of Canada grew its stake in Progyny by 384.8% in the first quarter. Royal Bank of Canada now owns 13,027 shares of the company's stock valued at $291,000 after purchasing an additional 10,340 shares in the last quarter. Amundi grew its stake in Progyny by 103.8% in the first quarter. Amundi now owns 11,419 shares of the company's stock valued at $264,000 after purchasing an additional 5,817 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its stake in Progyny by 6.0% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 252,032 shares of the company's stock valued at $5,630,000 after purchasing an additional 14,297 shares in the last quarter. Invesco Ltd. grew its stake in Progyny by 37.4% in the second quarter. Invesco Ltd. now owns 379,189 shares of the company's stock valued at $8,342,000 after purchasing an additional 103,253 shares in the last quarter. Finally, Walleye Capital LLC grew its stake in Progyny by 6.9% in the second quarter. Walleye Capital LLC now owns 12,080 shares of the company's stock valued at $266,000 after purchasing an additional 780 shares in the last quarter. Hedge funds and other institutional investors own 94.93% of the company's stock.

Progyny Stock Down 1.8%

Shares of NASDAQ PGNY opened at $17.67 on Friday. The stock has a market capitalization of $1.38 billion, a price-to-earnings ratio of 27.18, a PEG ratio of 1.04 and a beta of 0.99. The stock's fifty day simple moving average is $18.22 and its 200 day simple moving average is $21.76. Progyny has a 52-week low of $16.10 and a 52-week high of $28.75.

Progyny (NASDAQ:PGNY - Get Free Report) last issued its earnings results on Thursday, February 26th. The company reported $0.48 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.38 by $0.10. Progyny had a return on equity of 11.37% and a net margin of 4.54%.The business had revenue of $318.40 million for the quarter, compared to analysts' expectations of $314.26 million. During the same period in the previous year, the firm posted $0.42 EPS. The company's quarterly revenue was up 6.7% on a year-over-year basis. Progyny has set its FY 2026 guidance at 1.830-1.950 EPS and its Q1 2026 guidance at 0.420-0.450 EPS. As a group, analysts anticipate that Progyny will post 1.12 earnings per share for the current year.

Progyny Company Profile

Progyny, Inc is a New York-based fertility benefits management company that partners with employers and health plans to design and administer comprehensive family-building programs. The company's digital health platform integrates clinical expertise, patient support tools and data analytics to help members navigate fertility treatments, from in vitro fertilization (IVF) and egg freezing to surrogacy and adoption. By focusing on outcomes-based care, Progyny aims to improve success rates while controlling costs for its clients.

The core of Progyny's offering is its proprietary Smart Cycle® benefit, which bundles clinical, emotional and logistical support into a single package.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.